key: cord-0889161-snsvngnc authors: Li, Shijun; Jiang, Weijia; Huang, Junfei; Liu, Ying; Ren, Lijuan; Zhuang, Li; Zheng, Qinni; Wang, Ming; Yang, Rui; Zeng, Yi; Wang, Yi title: Highly sensitive and specific diagnosis of coronavirus disease 19 (COVID-19) by reverse transcription multiple cross displacement amplification-labelled nanoparticles biosensor date: 2020-08-28 journal: Eur Respir J DOI: 10.1183/13993003.02060-2020 sha: 10343b42e632aa1a6d8e85ad312abd954c7bab99 doc_id: 889161 cord_uid: snsvngnc BACKGROUND: The ongoing outbreak of the novel human coronavirus SARS-CoV-2 (also known as 2019-nCoV) has become a global health concern. Rapid and ease-to-use diagnostic techniques are urgently needed to diagnose SARS-CoV-2 infection. METHODS: We devised a reverse transcription multiple cross displacement amplification (RT-MCDA) coupled with nanoparticles-based biosensor (BS) assay (RT-MCDA-BS) for rapid, sensitive and specific diagnosis of COVID-19. Two primer sets were designed to target the open reading frame 1a/b (F1ab) and nucleoprotein gene (N) of SARS-CoV-2. A total of 183 clinical samples, including 65 patients with COVID-19 infections and 118 patients with other pathogen infections, were used to testify the assay's feasibility. The diagnosis results were visually reported using BS. FINDINGS: The designed assay was performed using a simple instrument which could maintain the reaction in a constant temperature at 64°C for only 35 min. The total procedure of COVID-19 RT-MCDA-BS test could be finished within 1 h. The COVID-19 RT-MCDA-BS could detect down to 5 copies of target sequences. Among 65 clinical samples from the COVID-19 patients, 22 (33.8%) positive results were obtained from face, nasal, pharyngeal and anal swabs via COVID-19 RT-MCDA-BS assay, while rRT-PCR assay only detected 20 (30.7%) positive results in these samples. No positive results were obtained from clinical samples with non-COVID-19 infections. INTERPRETATION: COVID-19 RT-MCDA-BS was a rapid, reliable, low cost and easy-to-use assay, which could provide an attractive laboratory tool to diagnose COVID-19 in multiple clinical specimens, especially for field, clinic laboratories and primary care facilities in resource-poor settings. In late December 2019, an outbreak of pneumonia caused by a novel human coronavirus SARS-CoV-2 (also referred to 2019-nCov) emerged in Wuhan, Hubei province in China [1, 2] . The novel emerging virus has rapidly spread across China, and to more than 200 countries/regions outside of China (World Health Organization, COVID-19 Situation Report-129) [3] . Data as of 28 May 2020, SARS-CoV-2 has affected more than 5,593,631 patients (353,334 deaths) worldwide (WHO, COVID-19 Situation Report-129). Due to its rapid spreading speed (R 0 3.28), possible fatal progression and strong infectivity, COVID-19 has stirred a grave global concern [4] . Hence, a rapid, easy-to-use and reliable test tool was urgently required for diagnosing infections, treating the patients and controlling the spreading of COVID-19. Early diagnosis of COVID-19 is extremely difficult only according to manifestations, which are highly variable [5] . The clinical manifestations of COVID-19 patients range from asymptomatic infection, non-specific flu-like clinical presentations (such as cough and fever) to respiratory failure [3] . Obvious clinical manifestations may occur in two days, even up to two weeks after exposure. Thus, designing a rapid and early diagnostic method, is vital for treatment and disease control. Currently, the definitive diagnosis of COVID-19 infections strongly relies on polymerase chain reaction (PCR)-based methods, such as reverse transcription PCR (RT-PCR) and real-time reverse transcription PCR (rRT-PCR) [5] . However, they require an expensive thermal cycle apparatus and very skillful laboratory workers. In addition, only 62% positive rate obtained by PCR-based technologies because of their sensitivity limitation among clinical diagnosed COVID-19 patients is not effective for control of infection [5, 6] . Thus, an easy-to-use and cost-effective test with higher sensitivity is needed as a first-line technique to tackle the COVID-19 in field and clinical settings. Recently, several loop-mediated isothermal amplification (LAMP) assays have been devised for rapid detection of COVID-19 in clinical and stimulated patient samples [7] [8] [9] . However, the developed COVID-19 LAMP assays only detect one target gene (Open reading frame 1a/b; F1ab). False-positive results could be produced when they were applied to detect clinical samples containing highly homologous sequences, such as gene from bat severe acute respiratory syndrome-like coronavirus (GenBank KY417152.1). In addition, LAMP results were reported via agarose gel electrophoresis, SYBR dyes or PH indicator. Particularly, the electrophoresis is a tedious and time-consuming process, and the assessment of color change with the unaided eye is potentially subjective in an ambiguous test caused by the low concentration of templates. Herein, novel techniques, which could overcome these technical difficulties, are continuously demanded. Multiple cross displacement amplification (MCDA) technique is an easy-to-perform and reliable diagnostic assay, which amplifies the target nucleic acid under conditions (usually between 58ºC and 69ºC) within a short time (20 min-40 min, usually 30 min) [10] . Only a simple equipment (such as a water bath, a heating block, even a thermo cup) is sufficient for MCDA test. The MCDA technique has been used for diagnosing various infectious diseases producing positive results from down to 3 copies of target sequence, which has shown its rapidity, simplicity, high specificity characteristics. [11, 12] . To achieve a simultaneous detection of multiple targets and rapid analysis of MCDA products, nanoparticles-based biosensor has been coupled with MCDA to achieve an objective detection results. Biosensor is simple, easy-to-conduct and low-cost, and does not need complex instrument and skilled personnel [13] . In this report, we devised a one-step, single-tube reverse transcription MCDA (RT-MCDA) coupled with nanoparticles-based biosensor (BS) assay (RT-MCDA-BS) (Figure 1 and 2) , which could diagnose COVID-19 by simultaneously detecting F1ab (open reading frame 1a/b) and N (nucleoprotein) genes. The whole detection process could be completed within 1 hour with high accuracy. Thus, the RT-MCDA-BS method may enable the diagnosis of COVID-19 easier, faster and more reliable, even in resource-limited settings. The nanoparticles-based biosensor (BS, 4 mm×60 mm), depicted in Figure 2A , consisted of a sample pad, a conjugate pad, a nitrocellulose membrane (NC membrane) with an absorbent pad assembled on a plastic adhesive backing card (Jie-Yi Biotechnology. Co., Ltd. Shanghai, China). The capture reagents, including anti-Dig (sheep anti-digoxigenin antibody, 0.25 mg/mL, Abcam. Co., Ltd.), anti-FITC (rabbit anti-fluorescein antibody, 0.2 mg/ml, Abcam. Co., Ltd.) and biotin-BSA (biotinylated bovine serum albumin, 4 mg/mL, Abcam. Co., Ltd.), were dispensed onto the NC membrane as the test line 1 (TL1), test line 2 (TL2) and control line (CL) , respectively, with each line separated by 5 mm.. The detector reagents (Dye streptavidin coated polymer nanoparticles, 129 nm, 10mg mL-1, 100mM borate, pH 8.5 with 0.1% BSA, 0.05% Tween 20 and 10mM EDTA) were sprayed onto the conjugate region of the biosensor. Thus, the biosensor can detect three targets, including two target products (F1ab MCDA amplicons and N MCDA amplicons) and a chromatography control. Finally, the assembled biosensors were cut into 4-mm dipsticks, and dryly stored at the room temperature for use. Two sets of RT-MCDA primers (F1ab-MCDA and N-MCDA primer sets), which targeted F1ab gene and N gene of COVID-19 (GenBank MN908947, Wuhan-Hu-1), were designed according the MCDA principle (Figure 3) . Each MCDA primer set consists of two displacement primers (F1 and F2), two cross primers (CP1 and CP2), and six amplification primers (C1, D1, R1, C2, D2 and R2). The specificity of F1aband N-MCDA primer sets were analyzed by National Center for Biotechnology Information BLAST. Moreover, the OligoAnalyzer online software (V3.1, Integrated DNA Technologies, Coralville, IA) was employed for primer dimer and secondary structure investigation. The details of RT-MCDA primer design, primer location, sequences and modifications were listed in Figure 3 and Table S1 . All oligomers were synthesized and purified by Tianyi-Huiyuan Biotech. Co., Ltd. (Beijing, China) at HPLC purification grade. The standard RT-MCDA (F1ab-MCDA/N-MCDA) was conducted in a one-step reaction in a 25-μl mixture containing 12. Two plasmids (F1ab-plasmid and N-plasmid), which contain the F1ab and N genes, respectively, were commercially constructed by Tianyi-Huiyuan Biotech. Co., Ltd. (Beijing, China). According to manual, the initial concentrations of F1ab-and N-plasmids were 5×10 8 copies/µl. Then, ten-fold serial dilutions (5×10 4 to 5×10 -2 copies) of F1ab-plasmid and N-plasmid were used to assess the limit of detection The analytical specificity of the COVID-19 RT-MCDA-BS assay was evaluated by comparing COVID-19 templates with the templates extracted from various viruses, bacteria and fungi (Table S2) . A total of 54 clinical samples (including face, anal, nasal, pharyngeal swabs) were obtained from acute phase and convalescent of COVID-19 sent to the Guizhou province CDC ( Table S3) . Analysis of these RNA templates using COVID-19 RT-MCDA-BS assay was approved by Guizhou province CDC. The pharyngeal, nasal and anal swabs samples were collected using a Flocked sterile plastic swab applicator, which was placed in a Universal Viral Transport Medium (UVIM) for viruses (HiDNA biotech. Co., Ltd.). For faecal sample, aliquots (approximately 1 g) of the stools were placed into a tube, which contained 1.5 ML of UVIM. Then, the faecal sample was centrifuged at 5000 g for 10 min, and the supernatant was placed into a new tube. Particularly, aliquots (200 µl) of UVIM (pharyngeal, nasal and anal swabs samples) and supernatant of faecal samples were subjected to extract the RNA templates, and the procedure only required 15 min using a rapid RNA Extraction Kit (TianLong Biotech. Co., LtD.). Aliquots of 5 µl of templates were used for conducting the RT-PCR and COVID-19 RT-MCDA-BS methods. The RNA templates extracted from different types of clinical samples were collected after rRT-PCR performance in Guizhou province CDC, which was conducted by officially approved clinical RT-PCR kit. The LoD (limit of detection) of RT-PCR diagnosis kit was 500 copies/mL according its manual. A Ct value is < 37, which is defined as a positive result for COVID-19 infection. A Ct value is >40, or no Ct value is obtained, which is defined as a negative result for COVID-19 infection. A Ct value between 37-40 is indeterminate, and the test should be examined again. In addition, 118 pharyngeal swabs samples collected from non-COVID-19 patients also were tested for validating the specificity of the COVID-19 RT-MCDA-BS method. In the COVID-19 RT-MCDA system, two core primers, including F1ab-CP1 and N-CP1 primer, are labeled at the 5' end with digoxigenin (Dig) and fluorescein (FITC), respectively. The new F1ab-CP1 and N-CP1 primers were termed as F1ab-CP1* and N-CP1*. Simultaneously, two components (biotin-14-dCTP and biotin-14-dATP) are added into the COVID-19 RT-MCDA reaction mixtures ( Figure 1A) . As shown in Figure 1C ). The details of nanoparticles-based biosensor (BS) were shown in Figure 2A . RT-MCDA assay were feasible for target sequence detection. Then, the optimal reaction temperature of 64ºC of COVID-19 RT-MCDA was also determined ( Figure S2 and S3). As shown in Figure 4 , the COVID-19 RT-MCDA-BS assay can detect down to 5 copies of either F1ab-plasmid or N-plasmid in a vessel. Of note, F1ab and N gene of COVID-19 were simultaneously amplified correctly with their own primers in a one-step, single-tube reaction ( Figure 4A) . The results obtained via BS were consistent with VDR reagent and real-time turbidity, while the VDR and real-time turbidity methods could not achieve multiple target detection (Figure 4B and 4C) . Most importantly, F1ab-and N-RT-MCDA assays also revealed a detection limit of 5 copies of target sequences in a reaction, which was in consistent with COVID-19 RT-MCDA assay (Figure S4, S5 and Figure 4) . The optimal reaction time required for the COVID-19 RT-MCDA-BS assay during the amplification stage was also tested. The lowest template level (5 ×10 0 copies of either F1ab-or N-plasmids displayed three red bands (TL1, TL2 and CL) when the isothermal reaction was conducted for 25 min at 64°C (Figure S6) . (Table S2) . This suggested that the COVID-2019 RT-MCDA-BS assay has a very good specificity. A total of 65 RNA samples from the acute phase and convalescent patients, which were initially detected using rRT-qPCR in Guizhou province CDC in 2020, were tested to verify the feasibility of our assay. Our COVID-19 RT-MCDA-BS assay (Table S3) .. The data suggested our COVID-19 RT-MCDA-BS assay is more powerful in detecting COVID-19 patients, especially for those with very low virus loads. Furthermore, no positive results were obtained from these samples collected from non-COVID-19 patients (Table S4 ). With the unexpected occurrence of SARS-CoV-2 infection in Wuhan, the novel human coronavirus has since spread within China and other regions/countries [14] . Hence, it is vital to develop adequate diagnosis techniques, which can provide a simple, rapid, reliable and easy-to-use strategy to detecting SARS-CoV-2 infection. (Table S2) . Furthermore, COVID-19 RT-MCDA-BS assay could simultaneously detects two target genes (F1ab and N) in a on-step isothermal reaction, which ensures the reliability for COVID-19 diagnosis, eliminating the chance getting false-positive or false-negative results compared to other COVID-19 diagnosis methods that only detects a molecular marker (e.g., F1ab biomarker). (Table S3 ). The lower diagnosis rate of rRT-PCR might be reasoned by the presence of inhibitors which specifically affect to the rRT-PCR assay or the low copy numbers of the SARS-CoV-2 RNA templates which is out of rRT-PCR assay's detection limit. Moreover, isothermal amplification-based assays, including MCDA-based methods (e.g., RT-MCDA-BS test), was less sensitive to various inhibitors, or was less affected by the presence of various salts from sample buffer, or could tolerate the inhibitory effect of the large amounts of nucleic acids [15] . Particularly, no positive results were obtained from non-COVID-19 samples, which further validated the analytical specificity of COVID-19 RT-MCDA-BS assay. We devised a method (COVID-19 RT-MCDA-BS) to diagnose COVID-19 using reverse transcription, multiplex detection and isothermal amplification coupled with a nanoparticles-based biosensor. Our data demonstrated that COVID-19 RT-MCDA-BS was a highly specific and sensitive diagnostic assay, and could be used as an attractive laboratory tool for diagnosis of COVID-19 in different types of clinical specimens. The diagnosis test of COVID-19 RT-MCDA-BS could be finished within 1h, and did not rely on expensive reagents and apparatus. Collectively, its rapidity, low cost and ease-to-use characteristics make the COVID-19 RT-MCDA-BS method an ideal tool for use in field, primary and clinical laboratories, especially for resource-poor settings. The authors report no conflicts of interest in this work. 1-8 represented the plasmid levels (each of F1ab-and N-plasmids) of 5x10 4 , 5x10 3 , 5x10 2 , 5x10 1 , 5x10 0 , 5x10 -1 , 5x10 -2 copies per reaction and blank control (DW). The plasmid levels of 5x10 4 to 5x10 0 copies per reaction produced the positive reactions. F1ab-F1 5'-ACACTTAAAAACACAGTCTGTAC-3' 23 nt Pharyngeal swab --Others S100 Pharyngeal swab --Others S101 Pharyngeal swab --Others S102 Pharyngeal swab --Others S103 Pharyngeal swab --Others S104 Pharyngeal swab --Others S105 Pharyngeal swab --Others S106 Pharyngeal swab --Others S107 Pharyngeal swab --Others S108 Pharyngeal swab --Others S109 Pharyngeal swab --Others S110 Pharyngeal swab --Others S111 Pharyngeal swab --Others S112 Pharyngeal swab --Others S113 Pharyngeal swab --Others S114 Pharyngeal swab --Others S115 Pharyngeal swab --Others S116 Pharyngeal swab --Others S117 Pharyngeal swab --Others S118 Pharyngeal swab --Others The F1ab-RT-MCDA reactions for detection of F1ab gene of COVID-19 were monitored by real-time measurement of turbidity (LA320c). Turbidity of >0.1 was considered to be positive as the threshold value was 0.1. Eight kinetic graphs (1) (2) (3) (4) (5) (6) (7) (8) were yielded at different temperatures (61-68°C, 1 o C intervals) with target template at the level of 5×10 2 copies (F1ab-plamid) per reaction. The graphs from 63°C to 65°C showed faster amplification. Figure S3 . Optimal amplification temperature for N-RT-MCDA primer set The N-RT-MCDA reactions for detection of N gene of COVID-19 were monitored by real-time measurement of turbidity (LA320c). Turbidity of >0.1 was considered to be positive as the threshold value was 0.1. Eight kinetic graphs (1) (2) (3) (4) (5) (6) (7) (8) were yielded at different temperatures (61-68°C, 1 o C intervals) with target template at the level of 5×10 2 copies (N-plasmid) per reaction. The graphs from 63°C to 65°C showed faster amplification. Figure S4 . Analytical sensitivity of F1ab-RT-MCDA-BS assay using serially diluted F1ab-plasmid templates A, BS applied for reporting the results; B, Real-time turbidity applied for reporting the results; C, VDR applied for reporting the results. BS (A)/Signals (B)/Tubes (C) 1-8 represented the F1ab-plasmid levels of 5×10 4 , 5×10 3 , 5×10 2 , 5×10 1 , 5×10 0 , 5×10 -1 , 5×10 -2 copies per reaction and blank control (DW). The plasmid levels of 5×10 4 to 5×10 0 copies per reaction produced the positive reactions. An emerging coronavirus causing pneumonia outbreak in Wuhan, China: calling for developing therapeutic and prophylactic strategies The clinical dynamics of 18 cases of COVID-19 outside of Wuhan, China Clinical features of patients infected with 2019 novel coronavirus in Wuhan The reproductive number of COVID-19 is higher compared to SARS coronavirus Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention ddPCR: a more sensitive and accurate tool for SARS-CoV-2 detection in low viral load specimens Rapid Detection of Novel Coronavirus (COVID19) by Reverse Transcription-Loop-Mediated Isothermal Amplification Rapid colorimetric detection of COVID-19 coronavirus using a reverse tran-scriptional loop-mediated isothermal amplification (RT-LAMP) diagnostic plat-form: iLACO A Single and Two-Stage, Closed-Tube, Molecular Test for the 2019 Novel Coronavirus (COVID-19) at Home, Clinic, and Points of Entry Rapid and sensitive isothermal detection of nucleic-acid sequence by multiple cross displacement amplification Multiple cross displacement amplification coupled with gold nanoparticles-based lateral flow biosensor for detection of the mobilized colistin resistance gene mcr-1. Frontiers in cellular and infection microbiology Current and Future Perspectives on Isothermal Nucleic Acid Amplification Technologies for Diagnosing Infections Antarctic thermolabile uracil-DNA-glycosylase-supplemented multiple cross displacement amplification using a label-based nanoparticle lateral flow biosensor for the simultaneous detection of nucleic acid sequences and elimination of carryover contamination Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding Tolerance of loop-mediated isothermal amplification to a culture medium and biological substances